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Wide variation in the surgical management of breast cancer exists at hospital, regional, national and international level. To
demonstrate whether variation in surgical practice observed at aggregate level between breast units persists following adjustment for
case-mix, individual patient-level data from the Trent Breast Screening Programme Quality Assurance database (1997–2003) was
analysed. Expected case-mix adjusted mastectomy rates were derived by logistic regression using the variables tumour size, site and
grade, patient age and year of presentation, employing the region’s overall case-mix adjusted practice as the reference population.
The region’s 11 breast screening units detected 5109 (3989 invasive) surgically managed primary breast cancers over the 6-year
period. A total of 1828 mastectomies (Mx) were performed (Mx rate 35.8%, 95% confidence interval: 34.5–37.1%). Significant
variation in mastectomy rates were observed between units (range 25–45%, Po0.0001), and persists following case-mix adjustment
(Po0.0001). Two-fold variation in observed to expected unit mastectomy rate coefficient is demonstrated overall (range 0.66–1.36),
increasing to almost four-fold variation in cancers less than 15 mm diameter (range 0.55–1.95). Significant variation in surgery for
screen-detected primary breast cancer is not explained by case-mix. Further research is required to investigate potential patient and
professional causative factors.
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Over the last 10 years, evidence of long-term randomised trials of
the surgical management of early (stage 1 and 2) breast cancer
have conclusively demonstrated equivalent survival rates in
women with cancers up to 40 and 50 mm diameter, when treated
with either mastectomy or breast-conservation surgery with
ipsilateral radiotherapy (van Dongen et al, 2000; Fisher et al,
2002a, b). Over the same period, evidence has emerged that
inclusion of patients in decisions about their health is associated
with improved physical and psychological outcomes (Wolberg,
1990; Fallowfield et al, 1994; Stewart, 1995). Such knowledge led to
a paradigm shift from the view of the patient as ‘a passive recipient
of medical intervention‘, to a client or partner (Rawling, 1992), and
the empowerment of patients in the decision-making process in
health care (Wolberg, 1990; Richards et al, 1995; Stewart, 1995;
Charles et al, 1999; Royal College of Surgeons of England, 2002).
Consequently, it was widely assumed that when offered a choice of
surgery, the majority of women would elect to undergo breast-
conservation surgery. Evidence suggests this has not been the case.
Variability in the surgical management of early breast cancer
has long been observed and reported at breast unit/hospital level,
and regional/state level, both within the UK and internationally
(Iscoe et al, 1994; Goel et al, 1997; Morrow et al, 2001; Sauven et al,
2003). The issue of geographic variation in mastectomy rates has
been highlighted in recent UK Department of Health documents,
where practice variation is referred to as a ‘post code lottery’ of
cancer management, and the concept of using the mastectomy to
lumpectomy ratio has been introduced as a performance indicator
of breast unit practice (Department of Health, 2000, 2001). The use
of raw treatment rates, unadjusted for the case-mix, has the
potential for providing a misleading impression of practice,
especially if based on small numbers of treated individuals.
The majority of published studies on the issue conclude that
significant variation in treatment exists, which cannot be explained
by case-mix alone (Nattinger and Goodwin, 1994; Iscoe et al, 1994;
Goel et al, 1997). However, these conclusions are based on
aggregated data analysis, which fail to take account of case-mix.
Trent was until recently one of the eight National Health Service
regions of England and Wales. Situated geographically in the
centre and east of England, it has a population of around 5 million,
approximately 2 500 000 females (2001 Census, 2004). The UK
National Health Service Breast Screening Programme (NHSBSP)
set up in 1988 invites all women aged 50– 64 years to attend
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routine mammography. The population eligible for screening by
the Trent Breast Screening Programme was 441 000.
Breast unit and regional guidelines exist for the management of
breast cancer in the UK, but vary as there are no specific national
guidelines on the surgical management of the disease. Each unit in
Trent has a set of treatment guidelines, which include indications
and relative indications for the different surgical options; for
example, indications for mastectomy are patient choice, tumour
size (typically 440 mm diameter clinical size), multifocal disease,
and contraindication to radiotherapy. Relative indications for
mastectomy are lobular carcinoma, multicentric carcinoma within
a single breast quadrant, central tumour; breast conservation likely
to result in an unacceptable aesthetic outcome, and breast-
conservation surgery where radiotherapy is likely to be associated
with high risk of complications. Guidelines often contain the
postscript that larger tumours may be managed by breast
conservation under certain circumstances; for example, where
tumour to breast size ratio permits an acceptable outcome in terms
of aesthetic result, patient survival and local recurrence risk. It
should be emphasised that such guidelines are designed to be
permissive; their content intended to promote sufficient flexibility
within the confines of known evidence, to facilitate optimal
collaboration in the decision-making process between patients and
their treating professionals.
The aim of this study was to demonstrate whether variation in
surgical practice observed at aggregate level between units over the
Trent region, reported in Trent Breast Screening Programme
annual reports (Reed, 2004), persisted following adjustment for the
characteristics of cases managed by the individual units.
METHODS
This observational study analyses quality assurance data collected
by the Trent Breast Screening Programme on women diagnosed
with breast cancer as part of the UK NHSBSP between April 1997
and April 2003. Individual patient-level data from the database was
anonymised prior to conversion into an SPSS data file. The
password-protected database and outputs were stored securely.
Since the main outcome of treatment data was binary, that is,
whether or not the woman had a mastectomy, multiple logistic
regression with SPSS for windows version 12 was employed to
analyse the dataset at individual patient level to confirm whether
observed unit level variations persist following adjustment for
case-mix (tumour size, site, patient age) and year of treatment. For
the purposes of this study, maximum tumour size was defined as
the greatest recorded diameter (invasive or noninvasive) where
tumours comprised both invasive and noninvasive components.
Year of treatment was included as a variable to reflect changes in
evidence-based practice over time. Age, maximum tumour size
and year of diagnosis were treated as continuous covariates.
Tumour grade was categorised into invasive grade 1, 2 and 3, and
noninvasive, and tumour site grouped into central and noncentral.
Applying the logistic model at an individual patient level, the
individuals’ probability of undergoing a mastectomy was calcu-
lated given their clinical covariates. Expected individual screening
unit mastectomy rates were calculated by the summation of
individual patient level probabilities of undergoing a mastectomy
across that particular unit. The ratio of observed to expected
mastectomies (Mx) for each breast-screening unit were then
calculated. Observed to expected ratios above 1.0 suggest that after
adjustment for case-mix, the unit has a higher than expected Mx
rate compared to the average (using overall case-mix adjusted
practice in Trent as the reference population). Conversely,
observed to expected ratios below 1.0 suggest a lower than
expected Mx rate compared to the average.
Case-mix adjustment was performed twice. The first analysis
incorporated the variables tumour size, tumour site, patient age
and year of screening. The second included tumour grade in
addition. The first analysis reflects information uniformly available
prior to surgical decision-making in all the region’s units, and thus
the variables upon which operative advice and decision-making
are based. Tumour grade is documented preoperatively in a
proportion of cases, and may influence guideline-based treatment
decision-making in certain units.
RESULTS
During the period April 1997 to April 2003, 792 570 women were
screened by Trent’s 11 Breast Screening Units, incorporating 13
static sites and nine mobile diagnostic units. Over the 6-year
period, 5179 primary breast cancers were diagnosed through the
programme, 5109 (3989 invasive) were managed surgically, 70 did
not undergo surgery. Advanced disease or ‘other clinical factors’
were stated as the reason for not undergoing surgery in the
majority of cases.
Breast units’ performance over the 6-year period was aggre-
gated. Annual fluctuations were inherent within most services.
Table 1 describes the characteristics of the tumours detected by
the Trent Breast Screening Program over the 6-year period.
Between 1997 and 2003, 1828 Mx were performed, giving an overall
Trent region mastectomy rate of 35.8% (95% confidence interval
(CI): 34.5– 37.1%).
Table 2 illustrates observed unit mastectomy rates and those
expected following case-mix adjustments for all cancers
(n¼ 5060). Significant variation in mastectomy rates is illustrated
across the 11 units, with individual unit Mx rates ranging from 25
to 45% (Po0.0001). Expected rates derived by logistic regression,
using the region’s overall case-mix adjusted practice as the
reference population, demonstrate a two-fold variation in ratio
of observed to expected unit mastectomy rate (range 0.66–1.36).
Units 6 and 10 demonstrate statistically significant lower (34%)
and higher (36%) than expected rates, respectively. In addition,
Unit 4 exhibits a 13% higher observed to expected mastectomy rate
ratio, although this just fails to reach statistical significance.
When case-mix data analysis was repeated including the tumour
grade variable, 105 out of 5109 (2%) cases were excluded due to
missing or incomplete data. Comparison of the results of the two
forms of data analysis revealed no difference in the ratio of
observed to expected unit mastectomy rates when case-mix
adjustment included or excluded tumour grade as a variable.
Thus, the observed variation in mastectomy rates across the 11
screening units demonstrated in Trent cannot be accounted for by
tumour size, site or grade, patient age or year of screening.
In total, 46% (2329 out of 5062) of the women included in the
study had small tumours (less than 15 mm diameter). The overall
Mx rate in this subgroup was 19.3% (442 out of 2293); 95% CI:
17.9– 21.1%, and again varied significantly (Po0.0001) across the
11 units from 10 to 35%. Within the subgroup, an almost four-fold
variation in observed to expected mastectomy rate ratio between
breast units is demonstrated (range 0.55– 1.95). Table 3 and
Figure 1 demonstrate variation in mastectomy rates for small (less
than 15 mm diameter) tumours.
DISCUSSION
This observational study of a single UK region’s breast-screening
practice demonstrates statistically significant treatment variation
in the surgical management of early stage breast cancer. The
study’s strength lies in the analysis of patient data at an individual
level. By correcting for case-mix and comparing observed and
case-mix adjusted Mx rates, a unit’s mastectomy rate is effectively
adjusted for any variation in the type of cases presenting to them.
To the authors knowledge this is the first study of this type
demonstrating persistent breast cancer surgical treatment varia-
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tion. The study demonstrates that variables other than those
included in the case-mix adjustment (tumour size, tumour site,
tumour grade, patient age and year of presentation) are
responsible for the variation observed.
The conclusions drawn from this study are based purely on
breast cancers detected by the breast-screening programme and do
not include those diagnosed through the symptomatic breast
service. Thus, the data analysis only accurately reflects unit
practice in the screen-detected subgroup, where the majority of
women (82%) are aged 50–64 years and have relatively small
tumours. The interunit variation in Mx rate demonstrated by this
study may be atypical of women with breast cancer, reflecting
Table 1 Clinical characteristics of Trent breast-screening programme quality assurance database patients, 1997–2003 (n¼ 5109)
Cases (n) Mean Median Std deviation Minimum Maximum
Age at diagnosis (years) 5109 59.1 58.8 6.2 45.3 95.0
Maximum tumour size (mm) 5062 18.5 15.0 14.3 0.5 220.0
n %
Year (financial) 1997/1998 652 12.8
1998/1999 802 15.7
1999/2000 799 15.6
2000/2001 917 17.9
2001/2002 866 17.0
2002/3 1073 21.0
Total (n) 5109 100
Overall type of surgery Conservation 3281 64.2
Mastectomy 1828 35.8
Total (n) 5109 100
Invasive status Invasive and mixed 3989 78.1
Noninvasive only 1120 21.9
Total (n) 5109 100
Tumour size (mm) o15 2329 46.0
X15–o20 995 19.7
X20–o30 1060 20.9
X30–o50 480 9.5
X50 198 3.9
Total (n) 5062 100
Tumour site Central/nipple region 288 5.6
Noncentral 4818 94.5
Total (n) 5106 100
Tumour grade Noninvasive 1120 22.2
Invasive grade 1 1209 23.9
Invasive grade 2 1870 37.0
Invasive grade 3 854 16.9
Total (n) 5053 100
Table 2 Observed vs expected mastectomies (Mx) by screening unit
1997–2003 (all cancers)
Unit
Total
cancers
(n)
Observed
(O) Mx
(n)
Observed
(O) Mx
(%) Rate
(%)
Expected
(E) Mx
(n)
Ratio
O/E (95% CI)
1 209 89 42.6 77 1.15 (0.93–1.42)
2 310 106 34.2 114 0.93 (0.76–1.12)
3 415 159 38.3 138 1.15 (0.98–1.35)
4 723 250 34.6 221 1.13 (1.00–1.28)
5 367 148 40.3 139 1.06 (0.90–1.25)
6 840 213 25.4 321 0.66 (0.58–0.76)
7 345 118 34.2 124 0.95 (0.79–1.14)
8 253 94 37.2 79 1.19 (0.96–1.46)
9 916 390 42.6 367 1.06 (0.96–1.17)
10 235 106 45.1 78 1.36 (1.11–1.64)
11 447 140 31.3 155 0.90 (0.76–1.06)
Trent 5060 1813 35.8 1813 1.00
The expected numbers at each screening unit are based on adjusting each unit’s case-
mix for age, tumour site, tumour size, year of screening. A total of 49 patients have
been excluded due to missing data.
Table 3 Observed vs expected mastectomies (Mx) by screening unit,
1997–2003
Unit
Total
cancers
(n)
Observed
(O) Mx
(n)
Observed
(O) Mx
(%) Rate
(%)
Expected
(E) Mx
(n)
Ratio
O/E (95% CI)
1 96 24 25.0 20 1.22 (0.78–1.82)
2 148 26 17.6 30 0.86 (0.56–1.26)
3 192 40 20.8 35 1.14 (0.82–1.56)
4 417 82 19.7 79 1.03 (0.82–1.28)
5 136 28 20.6 25 1.13 (0.75–1.64)
6 323 33 10.2 60 0.55 (0.38–0.77)
7 142 27 19.0 27 0.99 (0.65–1.14)
8 131 27 20.6 26 1.06 (0.70–1.54)
9 405 87 21.5 83 1.05 (0.84–1.29)
10 111 38 34.2 20 1.95 (1.38–2.67)
11 192 30 15.6 37 0.80 (0.54–1.14)
Trent 2293 442 19.3 442 1.00
Tumours less than 15 mm in diameter. The expected numbers at each screening unit
are based on adjusting each unit’s case-mix for age, tumour site, tumour grade and
year of screening. A total of 36 patients have been excluded due to missing data.
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variability only within the screened subgroup. Further research is
needed to determine whether or not unit variation exists in the
non-screen-detected population.
There are several potential limitations to this type of study and
analysis. One is the use of an inappropriate data set with large
amounts of missing data. We believe the study described uses
robust data; the data has been rigorously audited by the quality
assurance service and validated both externally and by the
surgeons of the originating breast units. In areas audited by the
study, the data was 98% complete; 109 cases (2%) excluded from
analysis due to missing or incomplete data.
Overall tumour size as determined histologically was used in the
analysis, rather than radiological tumour size. Evidence suggests
histological size and radiological tumour size correlate well, with
good reliability of radiological assessment of tumour size based on
ultrasound and mammography (Pain et al, 1992).
The present study employed overall Trent screen-detected breast
cancer population (1997 –2003) as the reference population. An
argument could be made that the reference population should be
the overall treated UK NHSBSP population. This would require
access to individual level data of the entire treated UK screen-
detected population, and though the absolute level of observed to
expected coefficients may have altered, the degree of variation
between units’ coefficients would not.
Another potential limitation of the study is that observations are
based on the data of a single UK region. Trent as a region and its
units may be atypical of other UK regions and their units. There is,
however, evidence that such variation in Mx rates occurs
throughout the UK at regional and unit level, in symptomatic
and screen-detected breast cancer practice, to a similar degree as
that identified in Trent (Sauven et al, 2003; Moneypenny, 2004a;
NHS Cancer Screening Programmes and Association of Surgeons
at BASO, 4 A.D., 2004).
The study concentrated on a small number of tumour
characteristics and patient’s age. Screening year was included as
a proxy for time changes in evidence-based practice. It is
recognised that other clinical factors, not included in the study’s
case-mix adjustment analysis, could fully or partially explain the
pattern of treatment variation observed. Variables included in the
analysis were chosen to reflect information routinely available at
the time of decision-making.
The analysis performed is based purely on the information
contained within an existing database; patients were not contacted
for the purposes of this study. Therefore, certain other variables of
interest, such as such as tumour to breast size ratio, radiological
tumour size and information on educational level, family income
and decision-making style, not recorded on the database, are
unavailable. Data such as postcode, which could have provided a
surrogate measure of socioeconomic profile and permit assess-
ment of whether distance of patient’s home to radiotherapy
treatment centre influences treatment rates, were not available
because data were anonymised at source.
The study was conducted on a screen-detected population where
approximately 85% of women diagnosed with primary breast
cancer had tumours less than 30 mm diameter. On the basis of
tumour size alone, the majority of women in this group were
eligible for a choice of treatment. Within the subgroup with small
tumours (total tumour size less than 15 mm diameter), there is an
almost four-fold variation in observed to expected coefficients
following case-mix adjustment. This finding concords with data
from another UK study by Sauven et al (2003) illustrating a similar
degree of variation in treatment at regional level in the UK in the
screen-detected subgroup with small tumours. The study by
Sauven, however, failed to adjust for case-mix.
Although the study does not include information on the non-
screen-detected breast cancer population, it is probable that
symptomatic and screening practice is similar as patients are
treated by the same team of health care professionals. The results
of a recent audit, presented at the annual meeting of the
Association of Breast Surgery at the British Association of Surgical
Oncology on 26th May 2004, demonstrate a similar pattern of
treatment variation at breast unit level for cancers presenting
symptomatically to 50 breast units in the UK over a 6 –12-month
period from April 2002 to 2003 (Moneypenny, 2004b).
The explanation of wide variation in mastectomy rates remains
unclear from both our study and available literature. Research is
needed to investigate the potential factors influencing choice of
surgery in breast cancer. The process involved in decision-making
with respect to surgery in this disease is complex; the final decision
being the result of primary tumour characteristics and commu-
nication between, and interaction of, multiple individuals each
with their own pre-existing characteristics and influences inter-
acting with each other over a series of encounters. Future studies
to elucidate surgical treatment variation in breast cancer need to
focus on the influence of both potential patient and professional
(specialist surgeon and nurse) factors on decision-making.
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